Abstract | OBJECTIVE: METHOD: The authors conducted an 8-week, placebo-controlled, double-blind study of E-EPA in 30 female subjects meeting Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder. RESULTS: Twenty subjects were randomly assigned to 1 g of E-EPA; 10 subjects were given placebo. Ninety percent of those in both groups completed all 8 weeks of the trial. Analyses that used random-effects regression modeling and controlled for baseline severity showed E-EPA to be superior to placebo in diminishing aggression as well as the severity of depressive symptoms. CONCLUSIONS: The results of this study suggest that E-EPA may be a safe and effective form of monotherapy for women with moderately severe borderline personality disorder.
|
Authors | Mary C Zanarini, Frances R Frankenburg |
Journal | The American journal of psychiatry
(Am J Psychiatry)
Vol. 160
Issue 1
Pg. 167-9
(Jan 2003)
ISSN: 0002-953X [Print] United States |
PMID | 12505817
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fatty Acids, Omega-3
- eicosapentaenoic acid ethyl ester
- Eicosapentaenoic Acid
|
Topics |
- Adult
- Aggression
(drug effects, psychology)
- Borderline Personality Disorder
(diagnosis, drug therapy, psychology)
- Depressive Disorder
(diagnosis, drug therapy, psychology)
- Double-Blind Method
- Drug Therapy, Combination
- Eicosapentaenoic Acid
(administration & dosage, analogs & derivatives)
- Fatty Acids, Omega-3
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Pilot Projects
- Psychiatric Status Rating Scales
- Treatment Outcome
|